Short Interest in Eterna Therapeutics Inc. (NASDAQ:ERNA) Decreases By 5.9%

Eterna Therapeutics Inc. (NASDAQ:ERNA) saw a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 51,300 shares, a drop of 5.9% from the June 30th total of 54,500 shares. Based on an average daily volume of 8,800 shares, the short-interest ratio is presently 5.8 days. Currently, 1.8% of the company’s shares are sold short.

Eterna Therapeutics Stock Performance

Shares of ERNA opened at $1.81 on Thursday. Eterna Therapeutics has a 1 year low of $0.84 and a 1 year high of $2.91. The company’s 50 day simple moving average is $1.92 and its 200 day simple moving average is $1.93. The company has a market capitalization of $9.79 million, a price-to-earnings ratio of -0.43 and a beta of 4.49. The company has a debt-to-equity ratio of 3.03, a quick ratio of 0.79 and a current ratio of 0.79.

Eterna Therapeutics (NASDAQ:ERNA) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($1.23) earnings per share for the quarter. The business had revenue of $0.05 million during the quarter.

Institutional Trading of Eterna Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ERNA. Vanguard Group Inc. raised its stake in Eterna Therapeutics by 30.6% during the third quarter. Vanguard Group Inc. now owns 24,898 shares of the company’s stock worth $54,000 after purchasing an additional 5,830 shares during the period. Avidian Wealth Solutions LLC acquired a new stake in shares of Eterna Therapeutics during the 1st quarter worth $36,000. Sippican Capital Advisors raised its position in shares of Eterna Therapeutics by 34.7% in the 1st quarter. Sippican Capital Advisors now owns 72,800 shares of the company’s stock worth $175,000 after buying an additional 18,750 shares during the period. Finally, Lake Street Advisors Group LLC acquired a new position in Eterna Therapeutics in the fourth quarter valued at $933,000. 70.55% of the stock is owned by institutional investors and hedge funds.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.